Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study

References

• Stovner LJ, Nichols E, Steiner TJ, et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954–976. doi:10.1016/S1474-4422(18)30322-3
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Kolodner K, Stewart WF, Liberman JN, Steiner TJ. The family impact of migraine: population-based studies in the USA and UK. Cephalalgia. 2003;23(6):429–440. doi:10.1046/j.1468-2982.2003.00543.x
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301–315. doi:10.1177/0333102410381145
   PubMed Web of Science ®Google Scholar
• Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17(1):15–22. doi:10.1046/j.1468-2982.1997.1701015.x
   PubMed Web of Science ®Google Scholar
• Takeshima T, Ishizaki K, Fukuhara Y, et al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache. 2004;44(1):8–19. doi:10.1111/j.1526-4610.2004.04004.x
   PubMed Web of Science ®Google Scholar
• Ueda K, Ye W, Lombard L, et al. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain. 2019;20(1):68. doi:10.1186/s10194-019-1012-1
   PubMed Web of Science ®Google Scholar
• Agostoni EC, Barbanti P, Calabresi P, et al. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019;20(1):92. doi:10.1186/s10194-019-1038-4
   PubMed Web of Science ®Google Scholar
• Loder E, Rizzoli P. Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018. Headache. 2018;58(Suppl 3):218–229. doi:10.1111/head.13375
   Web of Science ®Google Scholar
• Bordini CA, da Silva HM, Garbelini RP, Teixeira SO, Speciali JG. Effect of preventive treatment on health–related quality of life in episodic migraine. J Headache Pain. 2005;6(5):387–391. doi:10.1007/s10194-005-0233-7
   Google Scholar
• Dodick DW, Silberstein S, Saper J, et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache. 2007;47(10):1398–1408. doi:10.1111/j.1526-4610.2007.00950.x
   Web of Science ®Google Scholar
• Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology. 2011;77(15):1465–1472. doi:10.1212/WNL.0b013e318232ab65
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–1088. doi:10.1001/jamaneurol.2018.1212
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim B-K, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–1454. doi:10.1177/0333102418779543
   PubMed Web of Science ®Google Scholar
• Ayer DW, Skljarevski V, Ford JH, Nyhuis AW, Lipton RB, Aurora SK. Measures of functioning in patients with episodic migraine: findings from a double-blind, randomized, placebo-controlled Phase 2b trial with galcanezumab. Headache. 2018;58(8):1225–1235. doi:10.1111/head.13383
   PubMed Web of Science ®Google Scholar
• Ford JH, Ayer DW, Zhang Q, et al. Two randomized migraine studies of galcanezumab: effects on patient functioning and disability. Neurology. 2019;93(5):e508–e517. doi:10.1212/WNL.0000000000007856
   Web of Science ®Google Scholar
• Sakai F, Ozeki A, Skljarevski V. Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: a phase 2 randomized controlled clinical trial. Cephalalgia Rep. 2020;3:1–10.
   Google Scholar
• Martin BC, Pathak DS, Sharfman MI, et al. Validity and reliability of the Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.1). Headache. 2000;40(3):204–215. doi:10.1046/j.1526-4610.2000.00030.x
   Web of Science ®Google Scholar
• Rendas-Baum R, Bloudek LM, Maglinte GA, Varon SF. The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients. Qual Life Res. 2013;22(5):1123–1133. doi:10.1007/s11136-012-0230-7
   Web of Science ®Google Scholar
• Speck RM, Shalhoub H, Wyrwich KW, et al. Psychometric validation of the Role Function Restrictive domain of the Migraine Specific Quality-of-Life Questionnaire Version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine. Headache. 2019;59(5):756–774. doi:10.1111/head.13497
   PubMed Web of Science ®Google Scholar
• Cole JC, Lin P, Rupnow MFT. Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version 2.1. Cephalalgia. 2009;29(11):1180–1187. doi:10.1111/j.1468-2982.2009.01852.x
   Web of Science ®Google Scholar
• Sakai F, Fukuuchi Y, Iwata M, et al. Reliability and validity of the Japanese version of the migraine quality of life survey [in Japanese]. Neurological Therapeutics. 2004;21:449–458.
   Google Scholar
• Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–e2221. doi:10.1212/WNL.0000000000006640
   PubMed Web of Science ®Google Scholar
• Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol. 2018;18(1):188. doi:10.1186/s12883-018-1193-2
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second International Burden of Migraine Study (IBMS-II). Headache. 2013;53(4):644–655. doi:10.1111/head.12055
   PubMed Web of Science ®Google Scholar
• Torres-Ferrus M, Alpuente A, Pozo-Rosich P. How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patientʼs perspective. Curr Opin Neurol. 2019;32(3):395–404. doi:10.1097/WCO.0000000000000689
   Web of Science ®Google Scholar
• Reuter U. A review of monoclonal antibody therapies and other preventative treatments in migraine. Headache. 2018;58(Suppl 1):48–59. doi:10.1111/head.13302
   PubMed Web of Science ®Google Scholar
• Lipton RB, Gandhi SK, Fitzgerald T, et al.The impact of fremanezumab on migraine-specific health-related quality of life in episodic migraine (P4.115). Neurology. 2018;90(15 Supplement):P4.115.
   Google Scholar
• Lipton RB, Tepper SJ, Reuter U, et al. Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study. Neurology. 2019;92(19):e2250–e2260. doi:10.1212/WNL.0000000000007452
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Diener H-C, Ashina M, et al. Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology. 2019;92(20):e2309–e2320. doi:10.1212/WNL.0000000000007497
   PubMed Web of Science ®Google Scholar
• Buse DC, Rupnow MFT, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84(5):422–435. doi:10.1016/S0025-6196(11)60561-2
   PubMed Web of Science ®Google Scholar